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Mitochondria as a
Therapeutic Target in Heart Failure
Marina Bayeva, PHD,* Mihai Gheorghiade, MD,† Hossein Ardehali, MD, PHD*
Chicago, Illinois
Heart failure is a pressing public health problem with no curative treatment currently available. The existing ther-
apies provide symptomatic relief, but are unable to reverse molecular changes that occur in cardiomyocytes. The
mechanisms of heart failure are complex and multiple, but mitochondrial dysfunction appears to be a critical
factor in the development of this disease. Thus, it is important to focus research efforts on targeting mitochon-
drial dysfunction in the failing heart to revive the myocardium and its contractile function. This review highlights
the 3 promising areas for the development of heart failure therapies, including mitochondrial biogenesis, mito-
chondrial oxidative stress, and mitochondrial iron handling. Moreover, the translational potential of compounds
targeting these pathways is discussed. (J Am Coll Cardiol 2013;61:599–610) © 2013 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1021The 20th century has witnessed a dramatic improvement in
patients’ survival after adverse cardiovascular events. How-
ever, heart disease still remains the number one cause of
death in the industrialized world, affecting 27 million
people in the United States alone. With $40 billion in
annual costs and 1 of every 5 patients dying within 1 year of
diagnosis (1), HF has become a major public health prob-
lem. Although significant progress has been made in the
outpatient management of chronic heart failure (HF), post-
discharge mortality and rehospitalization rates within 60 to 90
days can be as high as 15% and 30%, respectively (2).
The primary goal of treating HF patients is restoration of
cardiac function. Recent studies show that heart function
can be successfully recovered in patients with HF, even after
structural alterations have occurred. Thus, failing myocar-
dium is “viable but dysfunctional” rather than irreversibly
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nary artery disease. This finding opens up an avenue for
rational design of treatments that target the cardiomyocyte
itself, not the indirect pathways that suppress neurohor-
monal axis or induce vasodilation.
The mechanisms underlying the development of HF are
multiple, complex, and not well understood. Although
virtually all aspects of myocyte physiology are altered in HF,
the past decade of research provided convincing evidence
that mitochondrial dysfunction may be an important event
in the development of hypertrophy and HF. First, genetic
mutations that disrupt mitochondrial function are associ-
ated with cardiac dysfunction in mice (3) and humans (4,5).
Second, currently available therapies for HF, such as
angiotensin-converting enzyme inhibitors and angiotensin
receptor II (ATII) blockers significantly improve survival in
ischemic and nonischemic HF, and their administration
also correlates with improved mitochondrial function (6,7).
Finally, it is important to note that cardiomyocytes in the
failing heart remain viable, although metabolically stunned,
and their function can potentially be rescued (8). Thus,
therapeutic efforts should venture beyond symptomatic re-
lief and focus on reviving the dormant myocardium by
targeting the underlying molecular defects in HF. In this
review, we discuss the changes that occur in the mitochon-
dria of failing myocardium, followed by an overview of the
pertinent therapeutic targets and approaches that can po-
tentially reverse these changes and preserve cardiac health.
Of note, we refrain from discussing the changes in glucose
and fatty acid utilization, as these topics have recently been
reviewed in detail elsewhere (8). Instead, we focus on
mitochondrial biogenesis, production of reactive oxygen species
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lular iron homeostasis as promis-
ing novel therapies for HF.
Mitochondrial Biogenesis
Pathophysiology. One of the ways
to augment energy production in the
setting of increased contractile de-
mand is to stimulate production of
new mitochondria, termed mito-
chondrial biogenesis. Mitochondria
contain 16.5 kilobase of circular
double-stranded DNA that en-
codes 13 protein components of
the electron transport chain and
needs to be replicated before the
division. In addition, as many as
1000 nuclear-encoded proteins
must be imported into the newly
formed mitochondria to make a
fully functional organelle (9).
Thus, generation of new mito-
chondria requires a coordinated
transcription of mitochondrial and
nuclear genomes orchestrated by
peroxisome proliferator–activated
receptor gamma coactivator 1
(PGC1) (10). PGC1, a nuclear-
encoded protein, is induced in
the states of enhanced energy
demand, such as increased car-
diac workload, high adenosine
diphosphate/adenosine triphos-
phate (ATP) ratio, cold, exercise,
and fasting (for review, see refer-
ences 11 and 12). High PGC1
activity is associated with in-
creased mitochondrial content,
as exemplified by cardiac-specific
PGC1 transgenic mice, which
exhibit uncontrolled mitochon-
drial proliferation and increase in
markers of mitochondrial bio-
genesis (13,14). PGC1 stimu-
lates mitochondrial proliferation
hrough its interaction with several transcription factors.
irst, PGC1 binds to and coactivates nuclear respiratory
actors (NRFs) 1 and 2, which in turn promote transcription
f nuclear-encoded genes targeted to mitochondria (15).
econd, PGC1 activates estrogen-related nuclear orphan
receptors ERR and , which induce expression of genes
nvolved in glucose and fatty acid uptake, energy produc-
ion, and ATP transport (16,17). Finally, PGC1 promotes
eplication of mitochondrial genome through NRF1/2-
Abbreviations
and Acronyms
AMPK  adenosine
monophosphate kinase
ATII  angiotensin
receptor II
ATP  adenosine
triphosphate
cGMP  cyclic guanosine
monophosphate
DFP  deferiprone
eNOS  endothelial nitric
oxide synthase
Fe/S  iron/sulfur
FRDA  Friedrich’s ataxia
HF  heart failure
I/R  ischemia/
reperfusion
MI  myocardial infarction
MnSOD  manganese
superoxide dismutase
mtDNA  mitochondrial
DNA
NO  nitric oxide
Nox  nicotinamide
adenine dinucleotide
phosphate (reduced form)
oxidase
NRF  nuclear respiratory
factor
PDE  phosphodiesterase
PDE5I  phosphodiesterase
type 5 inhibitor
PGC1  peroxisome
proliferator–activated
receptor gamma
coactivator 1
ROS  reactive oxygen
species
SOD  superoxide
dismutase
SS  Szeto-Schiller
Tfam  transcription
factor A
TPP  triphenylphosphoniumediated induction of mitochondrial transcription factor ATfam) (12). Cardiac-specific deletion of NRF1 (18),
RR (19), and Tfam (20) are all associated with decreased
itochondrial content or function, confirming their role in
itochondrial biogenesis.
Studies of rodents (21–23), dogs (24), and humans (25)
uggest that disruption of mitochondrial biogenesis repre-
ents an early event in the pathophysiology of HF, the
imely reversal of which is cardioprotective. Grossly, mito-
hondrial content and mitochondrial DNA (mtDNA) copy
umber are significantly reduced in rodent and human
ailing myocardium, and downregulation of the PGC1
pathway has been observed in various models of HF in mice
and rats (21,22,26,27). However, the role of PGC1 in
uman HF remains controversial, and contradictory results
ave also been reported (28–30). Because PGC1 is exten-
ively regulated on the post-translational level by phosphor-
lation (31), acetylation (32), and protein stabilization (33),
t is not clear whether PGC1 activity is reduced in the
failing hearts and whether the reduction in mitochondrial
number in HF in humans is due to deregulation of PGC1
signaling.
A defect in mtDNA replication was proposed as an
alternative mechanism for the reduction in mitochondrial
biogenesis (30,34). Importantly, changes in mtDNA repli-
cation machinery represented a very early event detected in
hypertrophied hearts that have not yet transitioned to failure
(30). The actual trigger for reducing mtDNA replication in
a setting of increased workload is unknown, and it would be
of interest to replicate these studies in animal models and/or
HF patients.
Therapeutic strategies. Despite the controversy about the
role of PGC1 in human HF, boosting mitochondrial
iogenesis in failing myocardium appears to be beneficial
35). In fact, the angiotensin-converting enzyme inhibitor
aptopril was shown to increase mitochondrial content in
he hearts of dogs after coronary ligation (36), suggesting
hat some of its beneficial effects may be due to the
timulation of mitochondrial biogenesis. Although currently
o drugs that specifically target mitochondrial biogenesis in
F are available, acceleration of this process through
denosine monophosphate–activated kinase (AMPK), en-
othelial nitric oxide synthase (eNOS), and other pathways
ay represent a promising therapeutic approach (Fig. 1).
ADENOSINE MONOPHOSPHATE–ACTIVATED KINASE.
AMPK exhibits very low baseline activity in the heart, but
is upregulated in response to a variety of stressors (37,38).
Importantly, activation of AMPK is thought to be the
mechanism driving the increase in mitochondrial biogenesis
in exercise-induced adaptive hypertrophy of the athlete’s
heart (39), which, unlike the pathological hypertrophy
discussed earlier, does not lead to HF. AMPK induces
PGC1 function (39,40), activates NRF1, Tfam (41), and
ERR (28), establishing this kinase as an important mod-
ulator of mitochondrial biogenesis.
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February 12 2013:599–610 Mitochondria and Heart FailureThe activity of AMPK is increased in failing hearts (42);
however, pharmacological activation of this pathway ap-
pears to exert additional cardiac protection. For example,
metformin, a commonly used antidiabetic drug that acti-
vates AMPK signaling, reduced infarct size and preserved
cardiac function in a long-term post-myocardial infarction
(MI) rat model in the absence of diabetes (43) and exhibited
cardioprotective properties in a rapid ventricular pacing
canine model (44). Gundewar et al. (45) found increased
PGC1 levels and preservation of heart function in wild-
type metformin-treated mice subjected to MI or ischemia/
reperfusion (I/R), but not in a AMPK knockout mouse
model (45). Although metformin was also shown to reduce
gluconeogenesis through direct inhibition of mitochondrial
complex I, the total cellular ATP content in the livers of
metformin-treated rats remained unchanged, consistent with
the maintenance of the cumulative mitochondrial bioenergetic
capacity possibly due to increased biogenesis (46).
Accumulating evidence of the cardioprotective properties
of AMPK in the setting of hypertrophy and cardiac failure
calls for the development of pharmacological agonists of
AMPK in the heart. Several clinically available compounds
have been shown to activate AMPK, including metformin,
5-aminoimidazole-4-carboxamide-1--D-ribofuranosyl 5=-
onophosphate (AICAR), thiazolidinediones, and statins.
oreover, the ATII receptor blocker telmisartan was shown
o increase phosphorylated AMPK levels in cultured
myotybes (7), suggesting that the beneficial effects of this
Figure 1 Mitochondrial Biogenesis
Mitochondrial biogenesis impairment is an early event in the development of hear
be enhanced therapeutically with the use of adenosine monophosphate kinase (AM
pathway (including phosphodiesteraes type 5 inhibitors), or resveratrol. All of thes
receptor gamma coactivator 1 (PGC1), nuclear respiratory factor (NRF)1/2, and
in the heart. ATP  adenosine triphosphate.drug may partially be due to stimulation of mitochondrial Tbiogenesis. However, the effect of current HF therapies on
the AMPK pathway is likely indirect via an increase in the
adenosine monophosphate/ATP ratio, inhibition of mito-
chondrial respiration, or other cellular and systemic effects
(47). Compounds targeting AMPK itself are currently in
development. Of note, compound A769662 by Abbott
Laboratories (Abbott Park, Illinois) is a specific allosteric
activator of AMPK complexes on the  subunit (48).
769662 reduced infarct size in rats fed low-fat and
igh-fat diets (49), providing proof-of-principle that a
irect activation of AMPK is beneficial to the heart.
nfortunately, the compound also inhibited 26S protea-
ome and caused cell-cycle arrest through an AMPK-
ndependent mechanism, limiting its clinical prospects (50).
nother small molecule, PT1, appears to activate AMPK1
nd AMPK2 isoforms by removing autoinhibition in the
atalytic subunits of the kinase (51). Thus, PT1 potentially
argets a vast array of AMPK complexes, although its effects
n the heart remain to be studied.
Several points must be considered when developing an
MPK agonist for the treatment of HF. First, AMPK
ctivation may only be suitable for treatment of HF due to
efined etiologies. Although AMPK activation was protec-
ive in the mouse models of MI and I/R, it failed to preserve
ardiac function in rats with chronic volume overload (52).
econd, AMPK is ubiquitously expressed and regulates an
rray of processes, and the subunit composition of AMPK
eterodimeric complex differs widely among tissues (53).
e, and reversal of this process is cardioprotective. Mitochondrial biogenesis can
gonists, stimulants of nitric oxide/cyclic guanosine monophosphate (NO/cGMP)
oaches stimulate nuclear-encoded proteins peroxisome proliferator–activated
ription factor A (Tfam), which, in turn, facilitate production of new mitochondriat failur
PK) a
e appr
transchus, to maximize clinical benefits and minimize toxicity,
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Mitochondria and Heart Failure February 12 2013:599–610specific isoforms of AMPK must be targeted. This principle
is exemplified by a finding that a gain-of-function mutation
in the AMPK2 subunit induces glycogen accumulation
nd progressive hypertrophic cardiomyopathy in humans
54). Studies examining expression patterns and functions of
ifferent AMPK isoforms will lay a foundation for the
evelopment of novel therapeutic agonists for the treatment
f HF.
ENOS/NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE
PATHWAY. Nitric oxide (NO) is a diffusible signaling mol-
ecule released by endothelial cells through the action of
eNOS, which enhances production of cyclic guanosine
monophosphate (cGMP) and leads to smooth muscle re-
laxation. This enzyme is also expressed in the heart where
NO and cGMP activate many potentially cardioprotective
pathways (55,56). Recent evidence suggests that the eNOS/
NO/cGMP pathway is an important activator of mitochon-
drial biogenesis (57,58). Mice transgenic for cGMP-
dependent protein kinase displayed a significant increase in
mitochondrial content, size, and upregulation of PGC1,
RF1, and Tfam in skeletal muscle (59). Treatment of
rimary brown adipocytes with NO donor also induced
itochondrial biogenesis through cGMP and PGC1
pathways and an increase in mean mitochondrial volume
density (60). Activation of the eNOS cascade also increased
mitochondrial content in several established cell lines (61),
whereas mtDNA and mitochondrial size were reduced in
the heart, liver, brain, kidney, and skeletal muscle of mice
with global eNOS knockout (61). The mechanism by which
the eNOS/NO/cGMP pathway induces mitochondrial bio-
genesis is unknown, although increase in calcium currents
and interaction with AMPK may play a role.
The eNOS/NO/cGMP pathway can be modulated phar-
macologically through inhibition of phosphodiesterases
(PDEs), which catalyze degradation of cGMP. PDE type 5
inhibitors (PDE5Is) were originally developed as a therapy
for cardiac angina, but are currently used in the treatment of
erectile dysfunction and pulmonary hypertension. Impor-
tantly, PDE5Is stimulate mitochondrial biogenesis through
upregulation of PGC1 and a subsequent increase in
tDNA content (62). Compelling evidence exists that
DE5Is can delay the progression of HF and reverse cardiac
emodeling in animal models and humans. Several small
linical trials found improvement in hemodynamic and
verall clinical measures in patients with congestive HF (for
eview, see reference 63), although larger samples sizes are
eeded to confirm the effect. A literature review from 1980
hrough 2011 found an improvement in cardiac index,
jection fraction, and other markers of heart function in
atients with the New York Heart Association functional
lass II or III HF treated with PDE5Is (64).
The role of PDE5I in the maintenance of mitochondrial
ass and function in failing hearts warrants further inves-
igation because the connection between eNOS/NO/
GMP pathway and mitochondrial biogenesis mostly comes irom studying noncardiac tissues and cell lines. Moreover,
ther PDE isoforms must be examined in relation to
itochondrial biogenesis specifically in the heart. In addi-
ion to inhibition of PDE, NO/cGMP synthesis may be
ctivated directly through maintenance of high eNOS
ctivity, especially during increased cardiac workload. He-
odynamic stress is known to uncouple eNOS, leading to
ts loss of activity and increased generation of ROS (65).
H4 (tetrahydrobiopterin) supplementation can prevent
NOS uncoupling and was found to reduce left ventricular
ypertrophy, cardiac dysfunction, and fibrosis in mice with
eart disease due to pressure overload (65,66). Importantly,
olic acid is known to replenish reduced BH4 and has been
hown to protect the heart through increased eNOS activ-
ty. Both folate deficiency and inhibition of BH4 synthesis
ere associated with reduced mitochondrial number and
unction (67,68), whereas folate administration to rats
ubjected to I/R preserved cardiac function (69). Finally, the
otential damaging effects of NO should be considered, as
his molecule was found to inhibit mitochondrial energy
roduction through reversible binding to cytochrome c and
isplacement of oxygen, which enhanced production of
OS and reactive nitrogen species (70). NO was also shown
o activate mitochondrial permeability transition pore open-
ng and to induce apoptosis (71).
RESVERATROL. Resveratrol, a polyphenol compound re-
sponsible for the cardioprotective properties of red wine,
was recently identified as a potent stimulator of mito-
chondrial biogenesis (72). Resveratrol activated both
eNOS (73) and AMPK (74,75), and enhanced mitochon-
drial biogenesis through upregulation of PGC1, NRFs,
nd Tfam (76). Treatment of mice with resveratrol
ncreased mitochondrial size and density, mtDNA con-
ent, mitochondrial enzyme activity, and oxidative capac-
ty in skeletal muscle. Functionally, these changes were
ssociated with improved motor function and a reduction
n resting heart rate (72).
The beneficial effects of resveratrol in the heart are well
ocumented. Two groups have independently shown that
esveratrol treatment prevents cardiac dysfunction in hyper-
ensive rats without reduction in blood pressure (75,77),
ndicating the direct influence of this compound on the
eart. Importantly, mitochondrial mass, biogenesis, and
unction were preserved by resveratrol in salt-sensitive
ypertensive rats (77) and rats transgenic for human renin
nd angiotensin genes (76). A small human clinical trial
ound significant improvement in diastolic heart function in
0 MI patients receiving 10 mg resveratrol daily during the
-month trial period. In addition, an improvement in
ndothelial function and reduction in low-density lipopro-
ein levels were noted in the treatment group, but mito-
hondrial biogenesis and function were not assessed (78).
mportant to note, however, is that resveratrol treatment
as found to be ineffective in reversing cardiac hypertrophynduced by volume overload in rats with an aortocaval shunt
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February 12 2013:599–610 Mitochondria and Heart Failure(79). Thus, the beneficial effects of this compound may be
limited to select clinical scenarios, such as hypertensive and
post-MI patients.
No significant toxicity of this compound was noted in
healthy human volunteers in phase I study during the
4-week trial period (80). Unfortunately, resveratrol has a
short half-life of 8 to 14 min and is extensively metabolized
in the body (81). Thus, an effective human dose cannot be
easily extrapolated from animal studies. Development of
more potent analogs with longer half-lives may help to
overcome these limitations.
OTHER STRATEGIES. The cardioprotective effects of estrogen
are well documented in various animal models. Moreover,
epidemiological studies reveal a reduced risk of cardiovascular
disease in premenopausal, but not post-menopausal, women
compared with men. Estrogen-like compounds were shown
to stimulate mitochondrial biogenesis through induction of
NRF1 expression and increase in mtDNA content (82).
Unfortunately, estrogen replacement therapy not only failed
to reduce, but actually increased, the number of cardiac
events in post-menopausal women (83). The likely reasons
for that are discussed by Mendelsohn et al. (84). Thus,
although the estrogen pathway represents a promising
therapeutic target, more research is needed to understand its
risks, benefits, and target patient population.
The approaches discussed here are aimed at the produc-
tion of new mitochondria via induction of PGC1, NRFs,
and Tfam signaling. However, it is also important to note
that mitochondria are dynamic organelles that constantly
undergo fusion and fission. Although the significance of
these processes in HF is not well understood, both fusion
and fission are essential for maintenance of mitochondrial
function (for review, see references 85 and 86). Constant
exchange of mitochondrial metabolites, proteins, DNA, and
Ca2 throughout the mitochondrial network by fusion/
ssion may protect these organelles in the setting of an
nsult. On the other hand, selective elimination of damaged
itochondria by the process of autophagy is also critical in
ardiac physiology, as disruption of autophagy in a pressure-
verloaded heart facilitates its transition into HF. Thus,
itochondrial biogenesis should be re-examined and tar-
eted in a broader context of preserving mitochondrial
umber, network organization, size, and quality.
itochondrial Oxidative Stress
athophysiology. Generation of ROS is significantly en-
anced in the failing myocardium, as has been unequivocally
hown by studies of animal models and human patients (for
eview, see references 87 and 88). The majority of ROS in
he heart appear to come from uncoupling of mitochondrial
lectron transport chain at the level of complexes I and III
89), although the view of mitochondria as a major source of
ntracellular ROS has been challenged (90). The activities of
itochondrial electron transport chain complexes are sup-
ressed in HF, and disruption of mitochondrial bioenergeticunction was found to increase ROS and oxidative DNA
amage (91), providing a possible pathophysiological link
etween mitochondrial dysfunction and ROS (88,92).
Nicotinamide adenine dinucleotide phosphate (reduced
orm) oxidase (Nox) is another important source of ROS in
he heart. Five isoforms of Nox have been described, with
ox4 being the most abundant in cardiomyocytes, endo-
helial cells, and fibroblasts. Nox4 localizes primarily to the
itochondria, does not require cytosolic subunits for its
ctivation, and is implicated in enhanced ROS production
n pressure overload and aging models of HF (93–95). Nox
ctivity is induced by pathways that are also active in
ysfunctional myocardium, including ATII stimulation,
umor necrosis factor-, and mechanical stretch (88). Nox
ctivity is high in human failing hearts (96), whereas genetic
eletion of this enzyme protects against cardiac dysfunction
nd remodeling in the MI mouse model (97).
The exact contribution of ROS to the development of
F is complex and remains a subject of intense debate. One
ikely mechanism is physical damage of cellular and mito-
hondrial structures, such as sarcomeric and excitation-
ontraction coupling proteins, which would impair the
echanical properties of the heart (98). Because the major-
ty of ROS in HF comes from mitochondria, these organ-
lles are the primary target of oxidative damage. mtDNA is
articularly sensitive to ROS due to the lack of protective
istones and less efficient DNA repair, and mutations in
tDNA-encoded genes are known to cause cardiomyopa-
hy. Moreover, reduction of PGC1 in failing hearts can
exacerbate oxidative stress and mitochondrial damage, as
this protein was found to maintain mitochondrial, but not
cytosolic, antioxidant defenses (99). In addition to damag-
ing cellular components, ROS regulate several signaling
cascades, including the known hypertrophic pathways such
as protein kinase C, mitogen-activated protein kinase, Jun
N-terminal kinase, and Ras (100). Finally, ROS facilitate
the remodeling of the extracellular matrix by inducing
matrix metalloproteinases through direct post-translational
modifications or indirectly through the nuclear factor B
pathway (101). Given that ROS affect virtually all aspects of
cardiomyocyte physiology, they represent an important
therapeutic target for treating HF. In support of this claim,
cardioprotective therapies such as angiotensin-converting
enzyme inhibitors and ATII receptor blockers were shown
to possess antioxidant properties, although it is not known
whether they target mitochondrial ROS directly or indi-
rectly (102,103).
Therapeutic strategies. Several trials have assessed the
efficacy of antioxidants in the treatment of HF, but the
results were disappointing. Long-term supplementation
with -tocopherol (vitamin E) was actually associated with
an increased risk of the development of HF (104). Evidence
from animal studies suggests that preferential inhibition of
ROS inside the mitochondria, rather than global antioxidant
treatment, may be cardioprotective. Overexpression of the
mitochondria-specific antioxidant peroxiredoxin-3 pro-
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Mitochondria and Heart Failure February 12 2013:599–610tected the heart against failure and remodeling in the mouse
model of MI (105). Similarly, overexpression of
mitochondria-targeted catalase attenuated hypertrophy in
pressure-overload (106) and hypertensive (107) mouse
models. Thus, scavenging ROS within the mitochondria
may protect the heart against the development of HF and
make it more resistant to stressful stimuli. Several ap-
proaches for targeting antioxidant compounds to the mito-
chondria are being explored and hold promise (Fig. 2).
MITOQ. The best characterized mitochondria-targeted an-
ioxidant to date is MitoQ, a quinol ROS scavenging moiety
inked to triphenylphosphonium (TPP), a lipophilic com-
ound that easily crosses membranes and accumulates in the
itochondrial matrix as a function of membrane potential.
cavenging of ROS is achieved through oxidation of MitoQ
nto its quinone form, which is then recycled back into the
ctive quinol by the action of mitochondrial complex II
108). MitoQ is bioavailable orally with no toxicity detected
hen administered to mice at an 20-mg/kg dose. Tracer
tudies found the compound to be rapidly taken up into the
eart, liver, brain, kidney, and muscle, with highest accu-
ulation in the heart and liver (109). Long-term adminis-
ration of MitoQ had no effect on plasma glucose, insulin,
ree fatty acid, or cholesterol levels, but was associated with
ignificantly reduced triglycerides. Affymetrix chip analysis
f the heart and liver tissue of mice receiving MitoQ
evealed no significant differences in gene expression profile
etween the treatment and control groups (110). Thus,
Figure 2 Targeting Mitochondrial ROS Production
Mitochondrial electron transport chain (ETC) complexes and nicotinamide adenine
amounts of reactive oxygen species (ROS) in failing hearts. Moreover, mitochondri
failure (HF). Although nonspecific antioxidants, such as vitamin E, show no benefit
approaches to targeting antioxidant compounds to mitochondria, including triphen
manganese superoxide dismutase/catalase mimetics, should be explored in the ditoQ is a safe, orally available small molecule that does not
ignificantly alter baseline physiology.
In WT mice, MitoQ does not lead to a significant
eduction in oxidative stress at baseline. However, admin-
stration of MitoQ to rats for 2 weeks reduced oxidative
tress and protected the heart against I/R injury using an ex
ivo Langendorff setup. These effects were specifically due
o the inhibition of ROS inside the mitochondria, as no
rotection was observed in control groups receiving either
ethyl-TPP, which can enter the mitochondria but does
ot scavenge ROS, or short-chain antioxidant quinol, which
s impermeable to the mitochondrial membrane (111).
hese findings were later confirmed in a mouse model of
/R and in an established cardiac cell line (112). MitoQ also
reserved cardiac function in a spontaneously hypertensive
at model of HF. However, this favorable outcome may also
e attributed to the reduction in blood pressure and im-
rovement in endothelial function observed in the MitoQ
roup (113). Finally, MitoQ was found to be protective in
ther models of mitochondrial oxidative stress, including
ardiac damage by doxorubicin (114), liver damage by
ipopolysaccharide (115), and protection of substantia nigra
rom 1-methyl-4-phenyl-1,2,3,6-tetrahydropryridine (mi-
ochondrial permeability transition pore) toxicity (116).
Two human trials assessed MitoQ’s efficacy in the treat-
ent of Parkinson’s disease (PROTECT) and in patients
ith chronic hepatitis C infection. Although the results of
he PROTECT trial were negative, it provided a wealth of
ata on the safety of the drug administered orally for as long
eotide phosphate (reduced form) oxidase 4 (Nox4) enzyme generate excessive
very sensitive to oxidative stress, and their function is severely impaired in heart
, targeting of ROS-scavenging molecules to mitochondria is protective. Various
phonium conjugation (MitoQ), Szeto-Schiller peptides, and synthesis of novel
ment of HF treatments.dinucl
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in HF
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February 12 2013:599–610 Mitochondria and Heart Failureas 1 year (117). On the other hand, the patients receiving 40
and 80 mg MitoQ in the chronic hepatitis C trial showed
significant improvement in hepatic function (118). Impor-
tantly, no severe side effects of the MitoQ regimen were
reported in either of the trials.
Despite the significant therapeutic potential of MitoQ
and other TPP-conjugated antioxidants, there are limita-
tions. The uptake of these compounds is governed by the
mitochondrial membrane potential, which may be severely
disrupted in failing hearts. Moreover, accumulation of
cationic TPP in the matrix can potentially depolarize
mitochondria, leading to unwanted side effects.
SZETO-SCHILLER PEPTIDES. Unlike TPP conjugates, the
small (10 amino acids) Szeto-Schiller (SS) peptides selec-
tively accumulate in the mitochondrial matrix independent
of membrane potential. SS peptides are rapidly taken up by
the mitochondria, with 1,000- to 5,000-fold accumulation
in this organelle compared with the cytosolic compartment
(119). Multiple variants of SS molecules have been synthe-
sized to date, and the tyrosine-containing SS-02 and SS-31
peptides hold therapeutic promise due to their antioxidant
properties (120). These products reduced mitochondrial
ROS production in cells treated with mitochondrial com-
plex I (121) and II and III (119) inhibitors. SS compounds
were also shown to be protective in vivo.
Administration of SS-31 before ischemia and before
reperfusion reduced MI size, lipid peroxidation indexes,
and increased ATP content in the rat heart (122).
Recently, SS-31, but not the nontargeted antioxidant
N-acetylcysteine, was shown to protect the heart from
cardiomyopathy due to angiotensin II administration or
Gq overexpression in mice (123), providing the first
vidence of SS-31 effectiveness in a more chronic model
f cardiac dysfunction.
Although peptides are typically considered poor candi-
ates for drug development due to the issues of solubility,
tability, rapid clearance, and inability to cross cellular
embranes, studies have revealed excellent pharmacokinetic
roperties of the SS peptides. These molecules are water
oluble due to the 3 net charge and are stable in an
queous solution at 37°C for 6 months. They can be
elivered via the intravenous, intraperitoneal, or subcutane-
us route and are rapidly distributed to highly perfused
rgans, including the heart, kidney, lung, and brain (120).
oreover, enzymatic degradation of the SS peptides is low,
nd they remain stable even after 2 h of incubation in whole
lood (124). Finally, the toxicity of SS compounds is low at
herapeutic doses, with no side effects observed after 5
onths of daily treatments in mice (125). Given these
avorable pharmacokinetic properties, SS peptides appear to
e good candidates for further testing in the treatment of
F. However, additional animal and human studies are
equired to validate these compounds as therapeutic candi-
ates. pMANGANESE SUPEROXIDE DISMUTASE/CATALASE MIMETICS.
Superoxide dismutases (SODs) are metal-containing anti-
oxidant enzymes that catalyze the conversion of superoxide
radical to hydrogen peroxide and O2. The mitochondria-
pecific manganese SOD (MnSOD or SOD2) is located in
he matrix, and its overexpression was shown to protect
gainst HF (126). Several inorganic MnSOD mimetics
ave been synthesized, and many of these compounds exert
rotection in conditions associated with oxidative stress (for
review, see reference 127). Salen derivatives, such as
UK-8 and EUK-134, possess antioxidant properties of
oth MnSOD and catalases and appear to be effective in
he heart. Although no studies have assessed the ability of
hese molecules to penetrate mitochondria directly, their
hemical properties (small, lipophilic, water soluble) and
ocumented ability to reduce mitochondrial ROS and
aintain activities of mitochondrial enzymes (128) sup-
ort this assumption.
Both EUK-8 and EUK-134 were found to protect
itochondria and the heart against various oxidative insults.
n an early study by Pucheu et al. (129), EUK-8 protected
ron-overloaded rat hearts from I/R injury, maintained left
entricular diastolic pressure, and preserved mitochondrial
ntegrity. EUK-8 treatment also prevented the development
f cardiomyopathy and maintained contractility and ATP
ontent in the heart/muscle-specific MnSOD2 knockout
ice, in which HF develops as early as 4 weeks after birth.
mportantly, ROS generation by isolated mitochondria was
ignificantly reduced by EUK-8 in these mice, suggesting
he ability of this molecule to offset mitochondrial oxidative
tress (130). Finally, EUK-8 ameliorated pressure overload-
nduced cardiac dysfunction in wild-type mice and mice
ith the deletion of mitochondrial antioxidant, apoptosis-
nducing factor (131). EUK-134, a more lipophilic deriva-
ive of EUK-8, exhibited similar protective properties in
ulmonary arterial hypertension–induced HF (132) and I/R
133) and reduced apoptosis in norepinephrine-stimulated
solated adult rat ventricular myocytes (134).
New SOD/catalase mimetics are being developed and
tudied, thus opening up an exciting new therapeutic
irection. However, most evidence of the mitoprotective
nd cardioprotective properties of these molecules come
rom genetic models of increased mitochondrial oxidative
tress. The mechanism of cardiac protection conferred by
UK-8/EUK-134 and related compounds must be thor-
ughly investigated. In particular, cardioprotective proper-
ies of these molecules may be independent of their antiox-
dant effects, as EUK-8 was reported to possess significant
asodilatory properties, which may increase oxygen and
utrient delivery to the heart and indirectly improve heart
unction (135).
ther strategies. As our understanding of the chemistry
ehind mitochondrial targeting is increasing, rational design
f novel therapies holds promise. A number of antioxidant
oieties have been conjugated to TPP and appear to conferrotection as well as control the degree of antioxidation and
p
g
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new molecules, it is important to understand various signal-
ing pathways that regulate mitochondrial antioxidant
defenses. A recent report by Lu et al. (99) found
antioxidant enzyme levels to be significantly decreased in
PGC1 knockout mice with pressure-overload hypertro-
hy, suggesting that enhancement of mitochondrial bio-
enesis and PGC1 expression by the strategies dis-
cussed earlier may have a positive effect on an antioxidant
profile as well.
Mitochondrial Iron Homeostasis
Pathophysiology. Although the role of mitochondrial iron
in HF has not been explicitly studied, indirect evidence
points toward potential therapeutic implications of altering
mitochondrial iron homeostasis in the diseased heart. Iron is
essential for maintenance of cellular viability and function
through its role in oxidative phosphorylation, antioxidant
enzyme activities, ribosome biogenesis, oxygen storage and
delivery, and more (136). Mitochondria are the key sites of
cellular iron processing where synthesis of iron/sulfur (Fe/S)
clusters and heme takes place, but are also the place where
ROS are generated (137). Being a reactive metal, free iron
catalyzes production of highly toxic hydroxyl radicals from
less reactive species such as hydrogen peroxide and super-
oxide anion via the Fenton reaction (138).
Although many studies examined changes in systemic
iron homeostasis in animals and humans with HF, very little
work has been done to characterize the intrinsic defects in
iron regulatory pathways of failing cardiomyocytes. In par-
Figure 3 Mitochondrial Iron as a Promising Therapeutic Target
Functional and structural damage to the mitochondria is a prominent feature of he
role in the regulation of cellular iron balance through the synthesis of heme and ir
eration of reactive oxygen species (ROS) and exacerbate damage. Reducing mitoc
tially protect failing hearts. Fe/S  iron/sulfur.ticular, mitochondrial iron regulation remains understudied.
Several lines of evidence suggest that accumulation of iron
in mitochondria can cause or exacerbate cardiomyopathy.
The best documented example is cardiomyopathy of Frie-
dreich’s ataxia (FRDA), a human genetic disease caused by
GAA triplet expansion in the frataxin gene. Although the
precise function of frataxin is unknown, it likely plays a role
in the regulation of mitochondrial iron homeostasis and
Fe/S cluster synthesis. In FRDA patients, progressive car-
diomyopathy develops that is characterized by extensive
mitochondrial dysfunction and oxidative damage (139).
Moreover, frataxin deficiency was associated with significant
accumulation of iron inside the mitochondria both in
patients (140) and in mouse models of the disease
(141,142), whereas no difference was detected in the total
iron content in FRDA hearts (140). Treatment of patients
with a combination of the mitochondria-permeable iron
chelator deferiprone and an antioxidant partially reversed
the cardiac phenotype observed in FRDA (143), supporting
the role of mitochondrial iron in the pathophysiology of
cardiac dysfunction. Another example of a cardiomyopathy
resulting from preferential iron accumulation in the mito-
chondria was reported by our group. We showed that
deletion of mitochondrial ATP binding cassette transporter
B8 reduces iron export from this organelle and leads to
mitochondrial iron overload. Mice with inducible knockout
of ATP binding cassette transporter B8 in the heart
displayed progressive systolic and diastolic dysfunction 8
weeks after gene deletion, which was associated with an
increase in oxidative stress, severe disruption of mito-
lure. In addition to generating adenosine triphosphate, mitochondria play a key
fur clusters. However, accumulation of iron in the mitochondria can catalyze gen-
al iron through development of mitochondria-permeable iron chelators can poten-art fai
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iron aggregates (144).
Whether iron accumulates in the mitochondria of
failing hearts due to common etiologies such as hyper-
tension and MI has not been examined directly. One
study used electron paramagnetic resonance spectroscopy
to analyze the iron status of the failing hearts in the
mouse model of cardiac-specific overexpression of Gq.
ignificant accumulation of iron inside cardiomyocytes
as noted, although the mitochondria-specific iron pool
as not been examined. However, activities of mitochon-
rial Fe/S cluster proteins were reduced in failing hearts,
nd the defect in complex III activity was specifically
ttributed to the lack of a Fe/S cluster center (145).
hese findings suggest deregulation of mitochondrial
ron processing in at least 1 model of chronic HF. Thus,
he defects in mitochondrial iron handling may contrib-
te to the development of HF through an ROS-
ependent mechanism and through potential disruption
f Fe/S cluster biogenesis.
herapeutic strategies. Extensive characterization of mi-
ochondrial iron homeostasis in various models of HF
ust be performed to target these pathways in the
ranslational studies. Reducing mitochondrial iron may
xert cardioprotection through inhibition of hydroxyl
adical formation and alleviation of oxidative stress (Fig. 3). The
herapy must be precisely targeted to the mitochondria,
s iron homeostasis is often disrupted in HF patients and
lobal iron deficiency is common (146). Instead of
helating iron on a systemic level and exacerbating iron
eficiency, the drug must remove free iron from the
itochondria and donate it to other cellular compart-
ents. Such redistribution of iron within a cell was
eported for deferiprone (DFP), an orally available re-
erse siderophore iron chelator. DFP was shown to enter
he cells, reduce mitochondrial free iron levels, exit cells
s an iron chelate, and transfer chelated iron to apotrans-
errin in the blood, thus potentially increasing systemic
ron availability (147). Oral administration of DFP to
RDA patients for 6 months significantly improved
eurological symptoms and reduced iron accumulation in
erebellar dentate nuclei, with no hematological side
ffects noted (148). Moreover, DFP and idebenone
reatment led to a partial reversal of FRDA cardiomyop-
thy in human patients (143). In addition to DFP,
nalogs of hydrophobic iron chelator pyridoxal isonicoti-
oyl hydrazone, such as 2-pyridylcarboxaldehyde isonic-
tinoyl hydrazone were shown to selectively remove
adioactive isotopes of iron from the mitochondria of
abbit reticulocytes (149) and were proposed as a poten-
ial therapy for FRDA and other diseases associated with
itochondrial iron overload (150). The effects of
-pyridylcarboxaldehyde isonicotinoyl hydrazone on sys-
emic iron homeostasis have not yet been examined.onclusions
itochondria are taking the center stage in our search for
ovel cardioprotective therapies, as their dysfunction ap-
ears early and invariably in the development of hypertro-
hy and HF. Maintenance of mitochondrial biogenesis
gainst cardiac insults and reduction in mitochondrial ROS
roduction are the 2 promising directions that may soon
ield effective treatments. Moreover, exploration and target-
ng of other vital mitochondrial processes in HF, including
egulation of iron homeostasis, should be actively pursued.
mportantly, our basic research and translational efforts
hould focus on targeting the intrinsic processes of viable,
ut dysfunctional, cardiomyocytes.
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